Amicus Therapeutics, Inc. (FRA:AM6)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.89B +102.9% |
| Revenue (ttm) | 540.16M +20.0% |
| Net Income | -23.09M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 12.30 |
| Previous Close | 12.13 |
| Day's Range | 12.30 - 12.30 |
| 52-Week Range | 4.80 - 12.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecu... [Read more]
Financial Performance
In 2025, Amicus Therapeutics's revenue was $634.21 million, an increase of 20.05% compared to the previous year's $528.30 million. Losses were -$27.11 million, -51.68% less than in 2024.
Financial numbers in USD Financial StatementsNews
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in...
Amicus Therapeutics Proxy statement: Proxy Filing
Amicus Therapeutics filed a proxy statement on February 23, 2026, providing details for shareholder voting and corporate governance matters.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions P...
Amicus Therapeutics Annual report: Q4 2025
Amicus Therapeutics has published its Q4 2025 annual report on February 20, 2026.
Amicus Therapeutics Earnings release: Q4 2025
Amicus Therapeutics released its Q4 2025 earnings on February 20, 2026, summarizing the period's financial results.
Amicus Therapeutics Slides: Q4 2025
Amicus Therapeutics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 20, 2026.
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fa...
Amicus Therapeutics Proxy statement: Proxy Filing
Amicus Therapeutics filed a proxy statement on February 2, 2026, providing details for shareholder voting and corporate governance matters.
Amicus Therapeutics Proxy statement: Proxy Filing
Amicus Therapeutics filed a proxy statement on January 26, 2026, providing details for shareholder voting and corporate governance matters.
Amicus Therapeutics Proxy statement: Proxy Filing
Amicus Therapeutics filed a proxy statement on January 21, 2026, providing details for shareholder voting and corporate governance matters.
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicu...
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
BioMarin to Buy Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Milli...
Amicus Therapeutics Proxy statement: Proxy Filing
Amicus Therapeutics filed a proxy statement on December 19, 2025, providing details for shareholder voting and corporate governance matters.
Amicus Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Strong revenue growth and profitability were highlighted, with Galafold and Pombiliti/Opfolda driving expansion in rare disease markets. The pipeline advanced with the DMX-200 FSGS program, and financial discipline remains a priority as the company eyes further late-stage asset deals.
Amicus Therapeutics Transcript: UBS Global Healthcare Conference 2025
Strong financial performance and product growth are driven by increased diagnosis, global expansion, and robust real-world data. Key catalysts include IP litigation outcomes, label expansions, and DMX-200 trial progress, with a focus on rare disease markets and stable pricing.
Amicus Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth, GAAP profitability, and record demand for Galafold and Pombiliti/Opfolda. Guidance for 2025 was reiterated, with strong growth expected in both core products and continued pipeline progress, including DMX-200 for FSGS.
Amicus Therapeutics Quarterly report: Q3 2025
Amicus Therapeutics has published its Q3 2025 quarterly earnings report on November 4, 2025.
Amicus Therapeutics Earnings release: Q3 2025
Amicus Therapeutics released its Q3 2025 earnings on November 4, 2025, summarizing the period's financial results.
Amicus Therapeutics Slides: Q3 2025
Amicus Therapeutics has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 4, 2025.
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N...
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...